Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Sep 8, 2015; 7(19): 2214-2219
Published online Sep 8, 2015. doi: 10.4254/wjh.v7.i19.2214
Published online Sep 8, 2015. doi: 10.4254/wjh.v7.i19.2214
Assessing cardiovascular risk in hepatitis C: An unmet need
Javier Ampuero, Manuel Romero-Gómez, Intercentre Unit of Digestive Diseases, Virgen Macarena - Virgen del Rocio University Hospitals. 41013 Sevilla, Spain
Author contributions: Ampuero J and Romero-Gómez M contributed to this paper.
Conflict-of-interest statement: None.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Javier Ampuero, MD, PhD, Intercentre Unit of Digestive Diseases, Virgen Macarena - Virgen del Rocio University Hospitals. Avenida Manuel Siurot, s/n, 41013 Sevilla, Spain. javi.ampuero@gmail.com
Telephone: +34-955-015761 Fax: +34-955-015899
Received: January 29, 2015
Peer-review started: January 30, 2015
First decision: March 20, 2015
Revised: April 13, 2015
Accepted: August 30, 2015
Article in press: August 31, 2015
Published online: September 8, 2015
Processing time: 222 Days and 22.3 Hours
Peer-review started: January 30, 2015
First decision: March 20, 2015
Revised: April 13, 2015
Accepted: August 30, 2015
Article in press: August 31, 2015
Published online: September 8, 2015
Processing time: 222 Days and 22.3 Hours
Core Tip
Core tip: Chronic hepatitis C is associated with significant morbidity and mortality, as a result of the progression towards cirrhosis and hepatocellular carcinoma. Furthermore, hepatitis C virus seems to be an independent risk factor for cardiovascular diseases due to its association with insulin resistance, diabetes and steatosis. The advent of new direct acting antiviral therapy has dramatically increased the sustained virological response rates of hepatitis C infection. In this scenario, the cardiovascular risk has emerged and represents a major concern after achieving the eradication of the virus.